Abbott Laboratories just paid its quarterly dividend of $0.63 per share on February 13, 2026, marking a 6.8% increase from ...

Feb 4 (Reuters) - Medical device maker Abbott Laboratories has reported 860 serious injuries linked to the recall of some of ...

Abbott Diabetes Care is recalling certain FreeStyle Libre 3 and FreeStyle Libre 3 Plus sensors due to falsely low glucose readings.

Abbott on Friday presented one-year clinical trial results for the Volt pulsed field ablation system alongside six-month CE ...

Abbott (NYSE: ABT) recently reported its Q3 results, with revenues and earnings slightly above our expectations. The company reported revenue of $10.64 billion and earnings of $1.21 on a per-share and ...

Forbes contributors publish independent expert analyses and insights. Bruce Japsen writes about healthcare business and policy. Abbott Laboratories $21 billion deal to acquire cancer test maker Exact ...

Last week, Abbott began the commercial launch of its new leadless pacemaker, which it believes is a historic development in the world of cardiac rhythm devices. Aveir DR is a better option than ...

Abbott Laboratories is undervalued by the market, despite its strong fundamentals and strategic moves in high-growth areas like diabetes care and weight-loss treatments. The company boasts a high net ...

Keep tabs on Texas politics and policy with our morning newsletter. The Texas Tribune Independent news. Trusted by Texans. About The Texas Tribune | Staff | Contact | Send a Confidential Tip | Ethics ...